| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Cohen David E | Director | C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO | /s/ Gregory S. Moss, Attorney-in-Fact | 12 Nov 2025 | 0001347383 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EVMN | Common Stock | Conversion of derivative security | +6,056 | +34% | 23,665 | 07 Nov 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EVMN | Series Seed Preferred Stock | Conversion of derivative security | -51,588 | -100% | 0 | 07 Nov 2025 | Common Stock | 6,056 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date. |